A budget impact analysis of natalizumab use in Ireland

Irish Journal of Medical Science

Volumn 181, Issue 2, 2012, Pages 199-204

  Dee, A ^a   Hutchinson, M ^b   De La Harpe, D ^c  

^a HEALTH SERVICE EXECUTIVE   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c Stewart's Hospital   (Ireland)

Author keywords

Budget impact analysis; Ireland; Multiple sclerosis; Natalizumab

Indexed keywords

NATALIZUMAB;

ARTICLE; BUDGET; CALCULATION; COST CONTROL; DRUG COST; DRUG USE; HUMAN; IRELAND; MULTIPLE SCLEROSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; BUDGETS; COST-BENEFIT ANALYSIS; HUMANS; IRELAND; MULTIPLE SCLEROSIS; NATIONAL HEALTH PROGRAMS;

EID: 84864276675     PISSN: 00211265     EISSN: 18634362     Source Type: Journal    
DOI: 10.1007/s11845-011-0773-6     Document Type: Article

References (12)

1. McGuigan C, McCarthy A, Quigley C, Bannan L, Hawkins S, Hutchinson M (2004) Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity. J Neurol Neurosurg Psychiatry 75(4):572-576 (Pubitemid 38406655)
2. McDonnell G, Hawkins S (1998) An epidemiologic study of multiple sclerosis in Northern Ireland. Neurology 50(2):423-428 (Pubitemid 28119783)
3. McGuigan C, Dunne C, Crowley J, Hagan R, Rooney G, Lawlor E et al (2005) Population frequency of HLA haplotypes contributes to the prevalence difference of multiple sclerosis in Ireland. J. Neurol 252(10):1245-1248 (Pubitemid 41443626)
4. Central Statistics Office, Cork (2008) Regional population projections 2011-2026
5. Gray OM, McDonnell GV, Hawkins SA (2008) Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland. Mult Scler 14(7):880-886
6. Mauskopf J, Sullivan S, Annemans L, Caro J, Mullins C, Nuijten M et al (2007) Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices- budget impact analysis. Value Health 10(5):336-347 (Pubitemid 47481105)
7. Orlewska E, Mierzejewski P (2004) Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 7(1):1-10 (Pubitemid 38186279)
8. Oturia A, Koch-Henriksen N, Petersen T, Jensen P, Sellebjerg F, Sorensen P (2009) Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 16:420-423
9. Putzki N, Kollia K, Woods S, Igwe E, Diener H, Limmroth V (2009) Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. Eur J Neurol 16:424-426
10. Health Service Executive, Dublin (2007) Report on neurology and neurophysiology services. (Unpublished)
11. National Centre for Pharmacoeconomics, Dublin (2007) Economic evaluation of natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated
12. Tappenden P, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J et al (2009) Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the medicare population. Value Health 12(5):657-665